Tokyo's Daiichi Sankyo aiming to innovate with help from UCSF

HONG KONG – Daiichi Sankyo Co. Ltd., the second largest pharmaceutical in Japan, has partnered with the University of California, San Francisco (UCSF), in a collaborative drug discovery program to develop therapeutics and diagnostics to treat degenerative diseases such as Alzheimer's disease, Parkinson's disease, Creutzfeldt-Jakob disease and frontotemporal dementias (FTD)